[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100582167":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":22,"locations":23,"responsibleParty":155,"collaborators":22,"id":157,"slug":22,"hasResults":158,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":22,"eligibilityCriteria":162,"healthyVolunteers":158,"sex":163,"minAge":164,"maxAge":165,"enrollmentInfo":166,"targetDuration":22,"studyType":169,"phases":170,"briefSummary":172,"conditions":173,"keywords":176,"overallStatus":26,"whyStopped":22,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":191},{"fullName":5,"class":6},"Sound Pharmaceuticals, Incorporated","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Open Label","EXPERIMENTAL","Oral administration of SPI-1005 400 mg BID",[13],"Drug: Ebselen",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Ebselen","Glutathione peroxidase mimetic",[9],[21],"SPI-1005",null,[24,43,58,69,84,95,110,125,140],{"facility":25,"status":26,"city":27,"state":28,"zip":29,"country":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":37},"The House Institute","RECRUITING","Los Angeles","California","90057","United States",{"type":32,"coordinates":33},"Point",[34,35],-118.24368,34.05223,{"lat":35,"lon":34},[38],{"name":39,"role":40,"phone":41,"phoneExt":22,"email":42},"Study Coordinator","CONTACT","(213) 443-8193","clinicaltrials@hifla.org",{"facility":44,"status":26,"city":45,"state":46,"zip":47,"country":30,"cosmosGeoPoint":48,"geoPoint":52,"contacts":53},"ENT and Allergy Associates of Florida","Boynton Beach","Florida","33471",{"type":32,"coordinates":49},[50,51],-80.06643,26.52535,{"lat":51,"lon":50},[54],{"name":55,"role":40,"phone":56,"phoneExt":22,"email":57},"Clinical Research Supervisor","954-575-9301","pamanley@entaaf.com",{"facility":44,"status":26,"city":59,"state":46,"zip":60,"country":30,"cosmosGeoPoint":61,"geoPoint":65,"contacts":66},"Delray Beach","33484",{"type":32,"coordinates":62},[63,64],-80.07282,26.46146,{"lat":64,"lon":63},[67],{"name":55,"role":40,"phone":68,"phoneExt":22,"email":57},"(561) 939 - 0186",{"facility":70,"status":26,"city":71,"state":72,"zip":73,"country":30,"cosmosGeoPoint":74,"geoPoint":78,"contacts":79},"Northwell Health","New Hyde Park","New York","11042",{"type":32,"coordinates":75},[76,77],-73.68791,40.7351,{"lat":77,"lon":76},[80],{"name":81,"role":40,"phone":82,"phoneExt":22,"email":83},"Clinical Research Manager","718-470-7974","gmullool@northwell.edu",{"facility":85,"status":26,"city":72,"state":72,"zip":86,"country":30,"cosmosGeoPoint":87,"geoPoint":91,"contacts":92},"ENT and Allergy Associates, LLP","10017",{"type":32,"coordinates":88},[89,90],-74.00597,40.71427,{"lat":90,"lon":89},[93],{"name":94,"role":40,"phone":82,"phoneExt":22,"email":83},"Ginny Mullooly",{"facility":96,"status":26,"city":97,"state":98,"zip":99,"country":30,"cosmosGeoPoint":100,"geoPoint":104,"contacts":105},"Thomas Jefferson University","Philadelphia","Pennsylvania","19107",{"type":32,"coordinates":101},[102,103],-75.16362,39.95238,{"lat":103,"lon":102},[106],{"name":107,"role":40,"phone":108,"phoneExt":22,"email":109},"Maya Childs","(215) 955-6760","Maya.Childs@jefferson.edu",{"facility":111,"status":26,"city":112,"state":113,"zip":114,"country":30,"cosmosGeoPoint":115,"geoPoint":119,"contacts":120},"Medical University of South Carolina","Charleston","South Carolina","29425",{"type":32,"coordinates":116},[117,118],-79.93275,32.77632,{"lat":118,"lon":117},[121],{"name":122,"role":40,"phone":123,"phoneExt":22,"email":124},"Research Director","(843)792-1356","nguyensh@musc.edu",{"facility":126,"status":26,"city":127,"state":128,"zip":129,"country":30,"cosmosGeoPoint":130,"geoPoint":134,"contacts":135},"University of Texas Southwestern","Dallas","Texas","75390",{"type":32,"coordinates":131},[132,133],-96.80667,32.78306,{"lat":133,"lon":132},[136],{"name":137,"role":40,"phone":138,"phoneExt":22,"email":139},"Paula Arellano-Cruz","214-648-8096","paula.arellano-cruz@utsouthwestern.edu",{"facility":141,"status":26,"city":142,"state":143,"zip":144,"country":30,"cosmosGeoPoint":145,"geoPoint":149,"contacts":150},"Medical College of Wisconsin","Milwaukee","Wisconsin","53226",{"type":32,"coordinates":146},[147,148],-87.90647,43.0389,{"lat":148,"lon":147},[151],{"name":152,"role":40,"phone":153,"phoneExt":22,"email":154},"Clinical Research Coordinator","414.955.0822","smleziva@mcw.edu",{"type":156,"investigatorFullName":22,"investigatorTitle":22,"investigatorAffiliation":22,"oldNameTitle":22,"oldOrganization":22},"SPONSOR","100582167",false,"NCT06859788","SPI-1005 for the Treatment of Meniere's Disease (Open Label)","Open-Label Study of SPI-1005 for the Treatment of Meniere's Disease","Inclusion Criteria:\n\n* Adult males\u002Ffemales, 18-75 years of age at the time of enrollment.\n* Diagnosis of probable or definite Meniere's Disease by AAO-HNS Amended 2015 Criteria.\n* At least two of three active symptoms (fluctuating hearing; tinnitus; aural fullness; vertigo or dizziness) of Meniere's disease, within 3 months of study enrollment.\n* Type A tympanogram at screening.\n* Air conduction thresholds ≤ 90 dB at all tested frequencies (250-8000 Hz) in both ears.\n* Subject is willing and able to provide informed consent and perform study procedures and assessments per protocol.\n* Reproductive requirements\n\nExclusion Criteria:\n\n* Current, or within 60 days prior to study enrollment, use of IV or intratympanic ototoxic medications such as chemotherapy including cisplatin, carboplatin, or oxaliplatin; aminoglycoside antibiotics including gentamicin, amikacin, tobramycin, kanamycin, or streptomycin; or loop diuretics including furosemide.\n* History of otosclerosis or vestibular schwannoma.\n* History of significant middle ear or inner ear surgery in the affected ear.\n* Conductive hearing loss with air-bone gap ≥15 dB, otitis media, or mixed hearing loss.\n* Significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, neurological, or psychiatric disease.\n* Current use or within 30 days prior to study enrollment systemic steroids.\n* Current use or within 7 days prior to study enrollment intratympanic steroids.\n* Hypersensitivity or idiosyncratic reaction to compounds related to ebselen or excipients.\n* Female patients who are pregnant or breastfeeding.\n* Participation in another investigational drug or device study within 30 days prior to study consent.\n* Participant resides more than 100 miles from the study site.","ALL","18 Years","75 Years",{"count":167,"type":168},200,"ESTIMATED","INTERVENTIONAL",[171],"PHASE3","Study of the safety of open-label SPI-1005 400 mg BID treatment in adults with Meniere's Disease (MD) for 6 or 12 months to support chronic or chronic intermittent use.",[174,175],"Meniere's Disease","Ménière's Disease",[177,178,179,180,181,21],"ebselen","hearing loss","tinnitus","vertigo","dizziness","2026-06-01",{"date":184,"type":185},"2026-06-02","ACTUAL",{"date":187,"type":185},"2025-10-29",{"date":189,"type":168},"2026-12",{"name":5,"class":6},9]